Back to Search
Start Over
HNRNPA1-induced spliceopathy in a transgenic mouse model of myotonic dystrophy
- Source :
- Proceedings of the National Academy of Sciences of the United States of America
- Publication Year :
- 2020
-
Abstract
- Significance Myotonic dystrophy type 1 (DM1) is a model for RNA-mediated disease in microsatellite expansion disorders. DM1 is caused by CTG expansions (CTGexp) and expression of CUGexp RNAs that sequester muscleblind-like (MBNL) proteins, while also triggering hyperphosphorylation of CUGBP1/ETR3-like factor 1 (CELF1). These proteins regulate developmental transitions in RNA processing, so DM1 is characterized by retention of fetal RNA processing patterns in adults. Although current evidence indicates that CELF1 is a specific antagonist of MBNL activity, this study reveals that another protein, HNRNPA1, is also downregulated during normal development but upregulated in DM1, where it also induces fetal splicing shifts. Thus, DM1 disease results from an imbalance in the expression of multiple RNA processing factors important for both proliferation and differentiation.<br />Studies on myotonic dystrophy type 1 (DM1) have led to the RNA-mediated disease model for hereditary disorders caused by noncoding microsatellite expansions. This model proposes that DM1 disease manifestations are caused by a reversion to fetal RNA processing patterns in adult tissues due to the expression of toxic CUG RNA expansions (CUGexp) leading to decreased muscleblind-like, but increased CUGBP1/ETR3-like factor 1 (CELF1), alternative splicing activities. Here, we test this model in vivo, using the mouse HSALR poly(CUG) model for DM1 and recombinant adeno-associated virus (rAAV)-mediated transduction of specific splicing factors. Surprisingly, systemic overexpression of HNRNPA1, not previously linked to DM1, also shifted DM1-relevant splicing targets to fetal isoforms, resulting in more severe muscle weakness/myopathy as early as 4 to 6 wk posttransduction, whereas rAAV controls were unaffected. Overexpression of HNRNPA1 promotes fetal exon inclusion of representative DM1-relevant splicing targets in differentiated myoblasts, and HITS-CLIP of rAAV-mycHnrnpa1-injected muscle revealed direct interactions of HNRNPA1 with these targets in vivo. Similar to CELF1, HNRNPA1 protein levels decrease during postnatal development, but are elevated in both regenerating mouse muscle and DM1 skeletal muscle. Our studies suggest that CUGexp RNA triggers abnormal expression of multiple nuclear RNA binding proteins, including CELF1 and HNRNPA1, that antagonize MBNL activity to promote fetal splicing patterns.
- Subjects :
- musculoskeletal diseases
congenital, hereditary, and neonatal diseases and abnormalities
microsatellite
Medical Sciences
Heterogeneous Nuclear Ribonucleoprotein A1
RNA-binding protein
Mice, Transgenic
Biology
Myotonic dystrophy
03 medical and health sciences
Exon
chemistry.chemical_compound
Mice
splicing
0302 clinical medicine
Fetus
CELF1
medicine
MBNL1
Animals
Humans
Myotonic Dystrophy
Myopathy
CELF1 Protein
030304 developmental biology
0303 health sciences
HNRNPA1
Multidisciplinary
Alternative splicing
RNA
RNA-Binding Proteins
Biological Sciences
medicine.disease
Cell biology
DNA-Binding Proteins
Alternative Splicing
Disease Models, Animal
chemistry
RNA splicing
medicine.symptom
030217 neurology & neurosurgery
Subjects
Details
- ISSN :
- 10916490
- Volume :
- 117
- Issue :
- 10
- Database :
- OpenAIRE
- Journal :
- Proceedings of the National Academy of Sciences of the United States of America
- Accession number :
- edsair.doi.dedup.....3f336c58f345eb86e4f33a206eb07aaa